ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1134

Genome-wide Association Study Identifies Novel Loci for Leukopenia Among TPMT and NUDT15 Normal Metabolizers Taking Azathioprine

Jacy Zanussi, Puran Nepal, Alyson Dickson, Laura Daniel, Peter Straub, Tyne Miller-Fleming, Wei-Qi Wei, Adriana Hung, Nancy Cox, Vivian Kawai, Jonathan Mosley, Michael Stein, QiPing Feng, Ge Liu, Ran Tao and Cecilia Chung, Vanderbilt University Medical Center, Nashville, TN

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Cohort Study, Drug toxicity, genetics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Genetics, Genomics and Proteomics Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Azathioprine is a thiopurine drug used for the treatment of several inflammatory and autoimmune conditions. However, its use is limited due to side effects, in particular hematopoietic toxicity. While variants in both TPMT and NUDT15 are associated with leukopenia, they only explain 25% of the risk. Little is known about the genetic factors associated with azathioprine-associated leukopenia among TPMT and NUDT15 normal metabolizers.

Methods: We conducted a genome-wide association study (GWAS) among 1,184 new users of azathioprine with race reported as White in the electronic health record who were TPMT and NUDT15 normal metabolizers, did not receive an organ transplant, and who received azathioprine for an autoimmune or inflammatory condition. Leukopenia was defined as a white blood cell count less than 3,000 cells/mm3 while taking azathioprine and all cases were adjudicated by review of clinical records. A total of 7,363,955 genotyped and imputed single nucleotide polymorphisms (SNPs) passed quality control. We used PLINK2 to test the association between the SNPs and azathioprine-associated leukopenia among 125 cases and 1,059 control subjects. Results were adjusted by demographic characteristics, indication for azathioprine, concurrent medications, last recorded azathioprine dose, and 10 genetic principal components.

Results: Cohort patients had an average age of 44.1+/-17.7 years at baseline and were predominantly female (n=772, 65.2%). The main indications for azathioprine were rheumatic conditions (n = 609; 51.4%) and inflammatory bowel disease/ulcerative colitis (n = 411; 34.7%); 134 were taking concurrent immunosuppressants. The mean last recorded azathioprine dose was 107.5+/- 55.4 mg/d. Two SNPs were associated with leukopenia at a GWAS level of significance (p< 5×10-8) after adjustment for clinical variables (Fig); rs11664064 (OR = 3.61; CI = [2.31, 5.66]; risk allele = C) is an intronic variant in PTPN2 (a gene that encodes protein tyrosine phosphatase non-receptor type 2 and regulates T-cell responses), and rs45566135 (OR = 3.65; 95% CI = [2.33, 5.72]; risk allele = C) lies downstream from PTPN2 and is in strong linkage disequilibrium with the PTPN2 intronic variant (r2 = 0.98). The minor allele frequency for both alleles is 0.0527872.

Conclusion: We describe novel variants in the PTPN2 locus associated with leukopenia among TPMT and NUDT15 normal metabolizers taking azathioprine for inflammatory or autoimmune conditions.

Supporting image 1

PTPN2 region and the associations with leukopenia (cases = 125; controls = 1059; total = 1184)


Disclosures: J. Zanussi, None; P. Nepal, None; A. Dickson, None; L. Daniel, None; P. Straub, None; T. Miller-Fleming, None; W. Wei, None; A. Hung, None; N. Cox, None; V. Kawai, None; J. Mosley, None; M. Stein, None; Q. Feng, None; G. Liu, None; R. Tao, None; C. Chung, None.

To cite this abstract in AMA style:

Zanussi J, Nepal P, Dickson A, Daniel L, Straub P, Miller-Fleming T, Wei W, Hung A, Cox N, Kawai V, Mosley J, Stein M, Feng Q, Liu G, Tao R, Chung C. Genome-wide Association Study Identifies Novel Loci for Leukopenia Among TPMT and NUDT15 Normal Metabolizers Taking Azathioprine [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/genome-wide-association-study-identifies-novel-loci-for-leukopenia-among-tpmt-and-nudt15-normal-metabolizers-taking-azathioprine/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genome-wide-association-study-identifies-novel-loci-for-leukopenia-among-tpmt-and-nudt15-normal-metabolizers-taking-azathioprine/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology